Privia Receives HFMA’s MAP Award for High Performance in Revenue Cycle for Seventh Straight Year

3 years ago

ARLINGTON, Va., June 27, 2022 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (Nasdaq: PRVA) announced that its network of affiliated…

Acer Therapeutics Announces Initiation of its Pivotal Phase 3 DiSCOVER Trial of EDSIVO™ (celiprolol) for the Treatment of Vascular Ehlers-Danlos Syndrome

3 years ago

NEWTON, Mass., June 27, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a clinical stage pharmaceutical company focused on…

P3 Health Partners Announces Inclusion in the Russell 3000® Index

3 years ago

HENDERSON, Nev., June 27, 2022 (GLOBE NEWSWIRE) -- P3 Health Partners Inc. (“P3” or the “Company”) (NASDAQ: PIII), a patient-centered…

Artelo Biosciences Presents Positive Pre-Clinical Results of ART26.12, a Novel FABP5 Inhibitor, in Alleviating Chemotherapy-Induced Pain

3 years ago

Presentation delivered by Professor Saoirse O’Sullivan at the 32nd Annual ICRS Symposium in Galway, Ireland on Sunday, June 26thSOLANA BEACH, Calif.,…

WIMI Hologram Academy: The Application of Virtual Reality Technology in Vehicle Driving Training System

3 years ago

HONG KONG, June 27, 2022 (GLOBE NEWSWIRE) -- WIMI Hologram Academy, working in partnership with the Holographic Science Innovation Center,…

SELLAS Life Sciences Provides Clinical Update for GFH009 Ongoing Phase 1 Clinical Trial

3 years ago

- No Dose-Limiting Toxicities Observed in Lymphoma and Acute Myeloid Leukemia Patients at All Dose Levels Studied To-Date - - Early Indications…

Hillstream BioPharma Announces Collaboration with Sapien Biosciences in Cancer Treatments

3 years ago

Investigating the synergy between HSB-1216, a Ferroptosis inducer, and Immune Checkpoint InhibitorsBRIDGEWATER, N.J., June 27, 2022 (GLOBE NEWSWIRE) -- Hillstream…

Mesa Laboratories Appoints Tony Tripeny to its Board of Directors

3 years ago

LAKEWOOD, Colo., June 27, 2022 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) announced the appointment of Tony Tripeny to its…

Noema Pharma Announces FDA Investigational New Drug (IND) Authorization for Orpheus Phase 2b Study of PDE10A Inhibitor Gemlapodect (NOE-105) in Childhood Onset Fluency Disorder

3 years ago

Efficacy and safety study evaluating gemlapodect (NOE-105) in adults with Childhood Onset Fluency Disorder (also known as stuttering)Top-line data expected…

Enzyvant Receives 2022 Rare Impact Industry Innovation Award from the National Organization for Rare Disorders (NORD) for Novel, Tissue-Based Therapy to Treat Ultra-Rare, Life-Threatening Pediatric Condition

3 years ago

Company honored for its work on RETHYMIC® (allogeneic processed thymus tissue-agdc), a one-time, treatment for congenital athymia, an ultra-rare, severe…